JP2023528415A5 - - Google Patents

Info

Publication number
JP2023528415A5
JP2023528415A5 JP2022574196A JP2022574196A JP2023528415A5 JP 2023528415 A5 JP2023528415 A5 JP 2023528415A5 JP 2022574196 A JP2022574196 A JP 2022574196A JP 2022574196 A JP2022574196 A JP 2022574196A JP 2023528415 A5 JP2023528415 A5 JP 2023528415A5
Authority
JP
Japan
Prior art keywords
cell
cells
exon
hematopoietic stem
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035691 external-priority patent/WO2021247856A2/en
Publication of JP2023528415A publication Critical patent/JP2023528415A/ja
Publication of JP2023528415A5 publication Critical patent/JP2023528415A5/ja
Pending legal-status Critical Current

Links

JP2022574196A 2020-06-03 2021-06-03 Ｃｒｉｓｐｒベースの塩基エディターシステムを使用した系列特異的抗原の阻害のための組成物及び方法 Pending JP2023528415A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063033970P 2020-06-03 2020-06-03
US202063033966P 2020-06-03 2020-06-03
US63/033,970 2020-06-03
US63/033,966 2020-06-03
US202163183791P 2021-05-04 2021-05-04
US63/183,791 2021-05-04
PCT/US2021/035691 WO2021247856A2 (en) 2020-06-03 2021-06-03 Compositions and methods for inhibition of lineage specific antigens using crispr-based base editor systems

Publications (2)

Publication Number Publication Date
JP2023528415A JP2023528415A (ja) 2023-07-04
JP2023528415A5 true JP2023528415A5 (https=) 2024-06-10

Family

ID=78831734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574196A Pending JP2023528415A (ja) 2020-06-03 2021-06-03 Ｃｒｉｓｐｒベースの塩基エディターシステムを使用した系列特異的抗原の阻害のための組成物及び方法

Country Status (9)

Country Link
US (1) US20240041923A1 (https=)
EP (1) EP4161535A4 (https=)
JP (1) JP2023528415A (https=)
KR (1) KR20230029632A (https=)
CN (1) CN116157135A (https=)
AU (1) AU2021285907A1 (https=)
CA (1) CA3180738A1 (https=)
MX (1) MX2022015237A (https=)
WO (1) WO2021247856A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021081244A1 (en) * 2019-10-22 2021-04-29 Fred Hutchinson Cancer Research Center Base editor-mediated cd33 reduction to selectively protect therapeutic cells
WO2023043858A1 (en) * 2021-09-14 2023-03-23 Vor Biopharma Inc. Compositions and methods for multiplex base editing in hematopoietic cells
JP2024543369A (ja) * 2021-11-09 2024-11-21 ブイオーアール バイオファーマ インコーポレーテッド Ｅｍｒ２修飾のための化合物及び方法
KR20250075694A (ko) * 2022-09-28 2025-05-28 리제너론 파마슈티칼스 인코포레이티드 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
CN118684759A (zh) * 2023-01-17 2024-09-24 武汉大学 用于治疗急性髓系白血病的成分和方法
WO2025030010A1 (en) * 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016337525B2 (en) * 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
KR20200017476A (ko) * 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
US11718659B2 (en) * 2017-08-28 2023-08-08 The Trustees Of Columbia University In The City Of New York CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
CA3110837A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2021081244A1 (en) * 2019-10-22 2021-04-29 Fred Hutchinson Cancer Research Center Base editor-mediated cd33 reduction to selectively protect therapeutic cells

Similar Documents

Publication Publication Date Title
JP2023528415A5 (https=)
Patel et al. From concept to cure: The evolution of CAR-T cell therapy
AU2017355218B2 (en) Immunologically discernible cell surface variants for use in cell therapy
JP2022517618A5 (https=)
Vera et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
US20190136230A1 (en) Genetically engineered cells and methods of making the same
US20220257796A1 (en) Recombinant ad35 vectors and related gene therapy improvements
AU2014265487A1 (en) Human application of engineered chimeric antigen receptor (CAR) T-cells
AU2017213661A1 (en) Administration of engineered T cells for treatment of cancers in the central nervous system
US20220380776A1 (en) Base editor-mediated cd33 reduction to selectively protect therapeutic cells
WO2020056170A1 (en) Reducing cd33 expression to selectively protect therapeutic cells
BR112021008263A2 (pt) materiais e métodos para tratamento de câncer
WO2021249384A1 (en) Compositions and methods for enhancing immune response
JP2023521410A (ja) 大型のアデノウイルスペイロードの組み込み
JP2025508721A5 (https=)
CN119095953A (zh) 细胞表面受体的表位工程
Migliorini et al. Keeping the engine running: the relevance and predictive value of preclinical models for CAR-T cell development
Caforio et al. AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation
EP4450614A1 (en) Treatment of leukemia by combining a hypomethylating agent in combination with engineered car-nk cells
Pedrazzani MOBILIZATION-BASED CHEMOTHERAPY-FREE ENGRAFTMENT OF GENE EDITED HEMATOPOIETIC STEM CELLS
WO2025231213A2 (en) Modified b cells and methods for use thereof
Leng et al. An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells
JP2024526851A (ja) モノカルボン酸トランスポーター１１の阻害によるがんの細胞治療
CN117136195A (zh) 抗egfr嵌合抗原受体